XBIO REPORT

FREE WEEKLY BIOTECH STOCK CATALYST REPORTS
CONTACT

Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data for Deramiocel for Upper Limb Function in Duchenne Muscular Dystrophy

October 6, 2026

NASDAQ: $CAPR

SAN DIEGO, Oct. 05, 2026 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced positive new data from its…

Source: Read More

Clinical Trial

$CAPR, Capricor Therapeutics Inc, clinical trials, Deramiocel, Duchenne Muscular Dystrophy, HOPE-3

Disclaimer: This site is for information only. Not investment advice.

Subscribe For A Premium Report To Maximize Your Returns

The FREE bio tech stock catalyst report ONLY includes companies with catalysts within the current week. Often, this may not be enough time to capture the pre-catalyst stock price movements. For MAX RETURNS. Subscribe to a premium report type below and you will receive reports with a longer outlook, allowing you to discover earlier entries to be positioned before a price move happens. Don’t miss out, maximize your return potential!

Choose your outlook window (each priced accordingly)

30 DAY

60 DAY

90 DAY

120 DAY

UNLIMITED

Get FREE Biotech Stock Catalyst Reports

Email